Cargando…
Simplified dosimetry for kidneys and tumors in (177)Lu-labeled peptide receptor radionuclide therapy
PURPOSE: To evaluate if satisfactory post-therapeutic image-based dosimetry can be achieved for Lu-177-DOTATATE treatments using a reduced number of image acquisitions to improve patient comfort and reduce economical costs. METHODS: 39 patients who underwent 147 treatment cycles of Lu-177-DOTATATE f...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209556/ https://www.ncbi.nlm.nih.gov/pubmed/35723797 http://dx.doi.org/10.1186/s40658-022-00473-z |
_version_ | 1784729979700903936 |
---|---|
author | Ardenfors, Oscar Nilsson, Joachim N. Thor, Daniel Hindorf, Cecilia |
author_facet | Ardenfors, Oscar Nilsson, Joachim N. Thor, Daniel Hindorf, Cecilia |
author_sort | Ardenfors, Oscar |
collection | PubMed |
description | PURPOSE: To evaluate if satisfactory post-therapeutic image-based dosimetry can be achieved for Lu-177-DOTATATE treatments using a reduced number of image acquisitions to improve patient comfort and reduce economical costs. METHODS: 39 patients who underwent 147 treatment cycles of Lu-177-DOTATATE for neuroendocrine tumors were included in the study. A total of 291 and 284 absorbed doses were calculated to kidneys and tumors, respectively. Single-point dosimetry was performed using one SPECT/CT image acquired at 1 d or 7 d post-treatment using a fixed effective half-life (T(eff)) or using a patient-specific T(eff) determined for the initial cycle. Also, dose-per-activity values, (D/A)(1), were determined from the first cycle and used to calculate doses for subsequent cycles. All absorbed doses were evaluated against “true” doses calculated using both the 1 d and 7 d images. The relation between tumor grade and absorbed doses was also investigated. All dosimetry was performed on SPECT images. RESULTS: Absorbed doses to kidneys were most accurate when single-point dosimetry was performed using 1 d images with median ratios in relation to “true” doses in total dose of 1.00 (IQR: 0.97–1.03) when using fixed T(eff) and 1.01 (IQR: 0.98–1.04) when using T(eff) from the initial cycle. Calculations based on the 7 d image were most accurate for tumors with corresponding ratios in total absorbed dose of 0.98 (IQR: 0.96–1.00) and 1.00 (IQR: 0.99–1.01) when using a fixed T(eff) or T(eff) from the first cycle, respectively. The (D/A)(1) approach performed worse, as 2 of 77 total absorbed doses to the kidneys deviated with > 30%, and tumor-absorbed doses were increasingly overestimated with every cycle. Absorbed doses, T(eff) and 1 d uptake were higher for G1 tumors than G2 tumors. CONCLUSION: Dosimetry can be performed with satisfactory accuracy when using single SPECT/CT images acquired at 1 d for kidneys or at 7 d for tumors. |
format | Online Article Text |
id | pubmed-9209556 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-92095562022-06-22 Simplified dosimetry for kidneys and tumors in (177)Lu-labeled peptide receptor radionuclide therapy Ardenfors, Oscar Nilsson, Joachim N. Thor, Daniel Hindorf, Cecilia EJNMMI Phys Original Research PURPOSE: To evaluate if satisfactory post-therapeutic image-based dosimetry can be achieved for Lu-177-DOTATATE treatments using a reduced number of image acquisitions to improve patient comfort and reduce economical costs. METHODS: 39 patients who underwent 147 treatment cycles of Lu-177-DOTATATE for neuroendocrine tumors were included in the study. A total of 291 and 284 absorbed doses were calculated to kidneys and tumors, respectively. Single-point dosimetry was performed using one SPECT/CT image acquired at 1 d or 7 d post-treatment using a fixed effective half-life (T(eff)) or using a patient-specific T(eff) determined for the initial cycle. Also, dose-per-activity values, (D/A)(1), were determined from the first cycle and used to calculate doses for subsequent cycles. All absorbed doses were evaluated against “true” doses calculated using both the 1 d and 7 d images. The relation between tumor grade and absorbed doses was also investigated. All dosimetry was performed on SPECT images. RESULTS: Absorbed doses to kidneys were most accurate when single-point dosimetry was performed using 1 d images with median ratios in relation to “true” doses in total dose of 1.00 (IQR: 0.97–1.03) when using fixed T(eff) and 1.01 (IQR: 0.98–1.04) when using T(eff) from the initial cycle. Calculations based on the 7 d image were most accurate for tumors with corresponding ratios in total absorbed dose of 0.98 (IQR: 0.96–1.00) and 1.00 (IQR: 0.99–1.01) when using a fixed T(eff) or T(eff) from the first cycle, respectively. The (D/A)(1) approach performed worse, as 2 of 77 total absorbed doses to the kidneys deviated with > 30%, and tumor-absorbed doses were increasingly overestimated with every cycle. Absorbed doses, T(eff) and 1 d uptake were higher for G1 tumors than G2 tumors. CONCLUSION: Dosimetry can be performed with satisfactory accuracy when using single SPECT/CT images acquired at 1 d for kidneys or at 7 d for tumors. Springer International Publishing 2022-06-20 /pmc/articles/PMC9209556/ /pubmed/35723797 http://dx.doi.org/10.1186/s40658-022-00473-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Research Ardenfors, Oscar Nilsson, Joachim N. Thor, Daniel Hindorf, Cecilia Simplified dosimetry for kidneys and tumors in (177)Lu-labeled peptide receptor radionuclide therapy |
title | Simplified dosimetry for kidneys and tumors in (177)Lu-labeled peptide receptor radionuclide therapy |
title_full | Simplified dosimetry for kidneys and tumors in (177)Lu-labeled peptide receptor radionuclide therapy |
title_fullStr | Simplified dosimetry for kidneys and tumors in (177)Lu-labeled peptide receptor radionuclide therapy |
title_full_unstemmed | Simplified dosimetry for kidneys and tumors in (177)Lu-labeled peptide receptor radionuclide therapy |
title_short | Simplified dosimetry for kidneys and tumors in (177)Lu-labeled peptide receptor radionuclide therapy |
title_sort | simplified dosimetry for kidneys and tumors in (177)lu-labeled peptide receptor radionuclide therapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209556/ https://www.ncbi.nlm.nih.gov/pubmed/35723797 http://dx.doi.org/10.1186/s40658-022-00473-z |
work_keys_str_mv | AT ardenforsoscar simplifieddosimetryforkidneysandtumorsin177lulabeledpeptidereceptorradionuclidetherapy AT nilssonjoachimn simplifieddosimetryforkidneysandtumorsin177lulabeledpeptidereceptorradionuclidetherapy AT thordaniel simplifieddosimetryforkidneysandtumorsin177lulabeledpeptidereceptorradionuclidetherapy AT hindorfcecilia simplifieddosimetryforkidneysandtumorsin177lulabeledpeptidereceptorradionuclidetherapy |